Log In
BCIQ
Print this Print this
 

RG7800, RO6885247

  Manage Alerts
Collapse Summary General Information
Company PTC Therapeutics Inc.
DescriptionSmall molecule survival of motor neuron 2 centromeric (SMN2) splicing modifier
Molecular Target Survival of motor neuron 2 centromeric (SMN2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSpinal muscular atrophy (SMA)
Indication DetailsTreat spinal muscular atrophy (SMA)
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$490.0M

$30.0M

$460.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/05/2011

$490.0M

$30.0M

$460.0M

Get a free BioCentury trial today